Text this: 103 | A PHASE 1 STUDY OF KITE‐363 ANTI‐CD19/CD20 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B‐CELL LYMPHOMA.